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Abstract

Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately
30% of breast cancer patients with poor prognosis. In addition, microRNAs are small
non-coding RNA that have been linked to many cancers. Here we investigate which
miRNAs are differentially regulated by HER2 overexpression. Using quantitative
reverse-transcription prolymerase chain reaction (QRT-PCR) and matching it with the
clinical data acquired from Dvinge, we find five candidate miRNAs. When comparing
the miRNAs’ effect on patient survival, only three miRNAs stand as good predictors of
patient survival outcome. These miRNAs are miR-146a-5p, miR-181d, and miR-195-5p.
When miR-146a-5p is up-regulated, which is the case in HER2 positive patients, survival
of patients drop significantly. In addition, miR-181d and miR-195-5p are down-regulated
in HER2. With these two miRNA having low levels, the patient survival drops. Therefore,
this data indicates that miR-146a-5p, miR-181d, and miR-195-5p are potential markers
for patient survival and that their expression levels are highly associated with HER2
overexpression.
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Chapter 1
Introduction

1.1: Cancer
For many decades, cancer has been rigorously analyzed in many laboratories and
population-based researched throughout the world. Due to the dedication of many
scientists, a plethora of information is found where we can peer into cancer. However,
even though scientists have been hard at work in understanding cancer, no complete cure
has been found for the disease. This leaves us with the fact that we have not understood a
lot about cancer. In order to realize what is yet unknown, we must talk about what we
already know about cancer.
Cancer occurs in patients due to a multitude of factors that changes the behaviors
of cells. There are six hallmarks of cancer that describes what a cancer cell needs to be
able to acquire in order to be cancerous. These hallmarks are: evading growth suppressors,
activating invasion and metastasis, enabling replicative immortality, inducing angiogensis,
resisting cell death, and sustaining proliferative signaling (Hanahan & Weinberg 2011).
Though diet is considered a major contributor to the formation of cancer cells (Willett
2000), the fundamental change in this formation is a genetic change. This change is a
mutation that produces a dominant oncogene that promotes tumor formation and
recessive tumor suppressor genes that keep tumors at bay (Hanahan & Weinberg 2000).
Oncogenes is a term used to described genes that, when over expressed,
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promote tumor formation, whereas tumor-suppressor genes are genes that inhibit tumor
formation and are generally down regulated in tumors. With enough accumulation of
mutation to oncogenes and tumor suppressor genes, any cell can turn into a cancer cell.
These cancer cells would then have the ability to proliferate indefinitely and generate
tumors (Lobo et al 2007). Therefore, it is apparent that the scientific community has a
large understanding and has progressed in the molecular mechanism of the cellular
machinery in tumorigenesis (Reya et al 2001). However, due to the immensely complex
nature that is the molecular and biochemical mechanism and pathways that control cell
behavior, there is a mass sum of information that has yet to be uncovered to better
understand and treat cancer.

1.2: Breast Cancer:
Because of the complex mechanisms that control cell behaviors, cancer can
manifest in different types. Among these types are solid tumors that are of epithelial
origin. These epithelial tumors account for a significantly large cancer burden derived
from many tissues such as breast, colon, ovary, lung, prostate, pancreas, and brain which
constitute 80% of cancers (Visvader & Lindeman 2008). In the United States, breast
cancer is the number one most common cancer in women and it is a leading cause of
death among these women second only to lung cancer (Centers for Disease Control and
Prevention [CDC], 2013). Breast cancer is the cause of more than 40,000 cancer-related
deaths recorded annually in the U.S. among women (Klonisch et al 2008). In order to
understand different types of breast cancer, we must briefly explore the morphology of
the breast and the molecules that affect them. The breast is made up of fat and imbedded
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in this fat is the mammary gland. The mammary gland is formed of branched ducts
terminating in lobular and alveolar units (Klonisch et al 2008). Different cell lineages
occupy different parts of the mammary gland. The myoepithelial cells line the basement
layer of both the ducts and alveoli. The ducts and the alveoli are formed by the ductal
epithelial cells and the alveolar epithelial cells respectively, with the alveolar epithelial
cells having the ability to produce milk (Klonisch et al 2008). The breast cells are highly
influenced by different signals from the body, such as growth factors and the hormones
estrogen and progesterone. On their surface, the cells contain receptors for these signals
that they keep at a controlled quantity. Overexpression of surface receptors can cause
alternations in the signaling cascade downstream of the receptor. These alterations can
cause a shift in cell proliferation rate and intercellular change that can cause genomic
instability and the transformation of normal cells into cancerous cells (Hanahan &
Weinberg 2000).
Furthermore, the overexpression of the surface receptors is caused by mutations in
the gene expression mainly. Therefore, based on gene microarray, it has been deduced
that there are five subtypes of breast cancer depending on their gene expression pattern.
These subtypes are: luminal A, luminal B, basal-like, normal-like, and human epidermal
growth factor receptor 2 (HER2) positive tumors (Perou et al 2000). Luminal A and
luminal B breast tumors are estrogen receptor positive (ER+), which means they
overexpress the estrogen receptor. However, the difference between luminal A and
luminal B tumors is dependent on the tumor grade. Tumor grades are scored from three to
nine based on the differentiation of the tumor cells. The differentiation ranges from welldifferentiated to poorly differentiated tumors with the former having the best prognosis
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and the latter having the worst. Luminal A is of the well-differentiated grade and luminal
B is among the poorly differentiated grade. Among all types of breast cancers, luminal A
has the best prognosis for the patient, along with the normal-like tumors (Metzger Filho
et al 2011). Basal-like tumors are tumors that are negative for ER, progesterone receptor
(PR), and HER2. The basal-like tumors generally are found in 10%-15% of all tumors
and carry with them bad prognoses for the patient (Perou 2011). In addition, some of the
tumors that are classified under one subtype or the other can carry genetic similarities
with tumors that are classified under a different subtype. For example, basal-like tumors
can be enriched with HER2 and yet still be under the basal-like tumor type (Perou 2011).
HER2 is one of those receptors, when overly expressed, can cause genomic
instability which can transform normal cells into cancer cells in the breast and thus is
considered an oncogene. The HER2 gene is located in the long arm of chromosome 17
(17q12). HER2 is named so because it shows high resemblance to the structure of the
human epidermal growth factor receptor (HER1). Furthermore, HER2 is also known by
other names for different reasons. It can also be called ErbB-2 because it shows similarity
to the avian erythroblastosis oncogene B (ErbB) (Coussens et al 1985).
HER2 is a ligand-independent receptor tyrosine kinase that can amplify the
signaling pathway from other growth factors (Citri & Yarden 2006). The extracellular
domain of HER2 stays in a constitutively active confirmation (Yan et al 2014). HER2 can
homodimerize and heterodimerize, and with the constant active confirmation, HER2
becomes the preferred dimerizing partner of HER1, HER3, and HER4. The dimerization
causes an autophosphorylation (attachment of a phosphate molecule) to the amino acid
tyrosine in the HER2 receptor which initiates the signaling cascade (Olayioye 2001).
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In normal cells, HER2 expression is responsible for cell survival, proliferation,
differentiation, migration and apoptosis (Olayioye 2001, Roy & Perez 2009). For that
reason, HER2 expression is tightly regulated. In approximately 30% of breast cancer,
HER2 is overexpressed, and this type of breast cancer is called a HER2-positive breast
cancer (Korkaya et al 2008). This overexpression causes an increase in the homo and
heterodimerization which promotes tumorogenic signaling cascade (Yan et al 2014).
HER2-positive breast cancer cases tend to have very low survival rates due to the overexpression of HER2 and its effect leading to tumorigenesis, increased invasiveness, and
metastasis (Sorlie et al 2001). Some of these HER2 signaling cascades invovles pathways
that include the phosphoinositide 3-kinase (PI3K/Akt) pathway, the Ras pathway, and the
NFκB pathway (Feldman et al 2007, Merkhofer et al 2010) (Figure 1.1)
HER2-positive breast cancer treatments include using antibodies and
chemotherapy. Among the antibodies, trastuzumab is well known as having a very
significant positive effect on HER2-positive breast cancer patients. Trastuzumab results
in an overall response rate of 20%-35% in previously untreated HER2-positive breast
cancer, resulting in progression free survival and overall survival. These results are
intensified with the combination of chemotherapy along with the trastuzumab treatment
(Roy & Perez 2009). However, despite the promising success of trastuzumab, most
HER2-positive breast cancer patients do not respond to trastuzumab regardless of
whether it is single-agent or combined with chemotherapy. In addition, for those patients
who do respond to trastuzumab, a big majority end up developing a resistance to the
antibody (Roy & Perez 2009). Understanding the pathway will help in locating better
targets for treatment or even better markers for an early diagnosis.
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Figure 1.1: HER2 pathway:
Depiction of the HER2 pathway affecting three major pathways according to literature.
Right branch is PI3K/Akt pathway leading to mTOR. Middle branch is the Ras and Raf
eventually leading to the MEK and ERK pathway. Left branch is the pathway eventually
leading to the NFκB pathway.
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1.3: microRNA:
MicroRNAs (miRNA) are small non-coding regulatory RNA that are, on average,
21 nucleotides long that regulate the expression of proteins post-transcriptionally. There
are over a thousand miRNA in human cells that are all produced first in the nucleus as
primary miRNA (pri-miRNA) in the shape of a stem-loop (Lee et al 2002). The miRNAs
are then cleaved by an RNase III enzyme called Drosha, which produces a ~70 nucleotide
product called pre-micro RNA (pre-miRNA) (Lee et al 2003). RNase III enzymes are
proteins that are dsRNA-specific endonucleases that produce staggered cuts on both sides
of the RNA helix (Filippov et al 2000). Once pre-miRNA is produced, it is shuttled out of
the nucleus and into the cytoplasm to be processed by another RNase III enzyme called
Dicer. Dicer cleaves the loop from the pre-miRNA producing a ~21 nucleotide double
stranded miRNA (Lee et al 2002). The desirable strand of the double stranded miRNA is
separated and is placed in the RNA-induced silencing complex (RISC) while the
undesired strand – called the passenger strand – is degraded (Okamura et al 2008, Rana
2007). RISC is a ribonucleoprotein complex which contains RNA and proteins and can
also be known as miRNP (Schwarz & Zamore 2002) (Figure 1.2).
The proteins from the Argonaute (Ago) protein family are essential for the
function of RISC. The Ago proteins contain binding domains that help bind and orient
the mature miRNA to interact with the targeted messenger RNA (mRNA). RISC silences
mRNA translation by either inhibiting translation or degrading the mRNA. When there is
complete complementarity between the miRNA in RISC and the mRNA, the mRNA gets
degraded. However, when there is only partial complementarity between the miRNA in
RISC and mRNA, there is only silencing of the mRNA and inhibition of translation. The
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silencing and degradation occurs in many different ways, including binding to the 3
prime untranslated region (3’-UTR) of the mRNA and/or decapping the 5’ cap of the
mRNA (Filipowicz et al 2008, Schwarz & Zamore 2002). Therefore, because miRNA are
regulatory RNA, they are generally tightly regulated.
When regulation of miRNAs becomes faulty, alterations of miRNA expression
can occur and would be associated with many malignant human ailments such as cancer
(Bartel 2009). miRNAs’ DNA sequences have been reported in many deletion and overexpression sites of other genes. This means that they may be expressed or repressed along
with the expression or repression of the DNA where they were located (Calin et al 2004).
Likewise, miRNAs have also been suggested to act as tumor initiation miRNAs
(oncomirs) or tumor suppressor miRNAs depending on their targeted genes (EsquelaKerscher & Slack 2006). For example, if a miRNA targets HER2, then it is considered a
tumor suppressor miRNA because HER2 is an oncogene and would generally be downregulated or suppressed in cancer. On the other hand, miRNAs that target p53, a wellknown tumor suppressor gene, are considered oncomirs, and their expression is generally
up-regulated in cancer. An example of a tumor suppressor miRNA is miR-195-5p that is
normally down-regulated and has been observed to show suppressive capabilities in
hepatocellular carcinomas (Wang et al 2013). In addition, miRNAs have also been
proposed to be used as biomarkers for cancers as a way of identifying the types of
cancers that are involved, such as miR-146a-5p as a biomarker for colorectal tumor
localization (Iorio et al 2005, Omrane et al 2014).
Though many miRNAs have been studied extensively in many cancers, miRNA
regulations in breast cancers – specifically HER2-positive breast cancers – were not
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researched as extensively. Consequently, there remains a whole host of miRNAs and
their pathways that can be explored to further our understanding of the molecular
mechanism by which HER2-positive breast cancer functions. Since HER2 regulates and
increases tumor survivability, invasiveness, and metastasis, disrupting the signal cascade
that results from the regulation of miRNA may aid in slowing down tumor progression
and lead to a better prognosis for patients.

1.4: Clinical implications:
HER2 positive breast cancer patients are ~30% of the total breast cancer patient
population and generally have extremely low prognosis (Korkaya et al 2008). Although
some drugs have been established to have some positive effect on HER2 positive cancer,
such as trastuzumab, the number of patients that respond to the treatment are low, and the
drug activity is diminished after a while (Roy & Perez 2009). Therefore, it is important to
better understand the complex HER2 pathway to develop better treatments and drugs that
have more specific and effective targets.
Part of understanding the HER2 positive cancer is to understand how miRNAs are
involved in the HER2 pathway. It is known that miRNAs are involved in many pathways
in cancer and serve as biomarkers for cancer identification. However, miRNAs’
involvement in the HER2 pathway has scarcely been studied, and there remain many
avenues to discover regarding HER2 and miRNAs. Therefore, we propose that the HER2
overexpression will lead to differential regulation of a number of miRNAs that can help
HER2 maintain the cancer’s tumorigenicity.
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Figure 1.2: miRNA processing pathway:
The miRNA processing pathway starts off in the nucleus. Drosha and Dicer are two
RNase III enzymes for processing RNA. Pri-miRNA is the primary-miRNA. Pre-miRNA
is the prequel-miRNA. Ago 2 is argonaute protein that form the RISC with mature
miRNA.

10

Chapter 2
Materials and Methods

2.1: Cell Culture:
MCF10A-Vector and MCF10A-HER2 cells were provided courtesy of Emily
Wang, Ph.D. from the Institute of City of Hope. Culturing MCF10A cells requires
DMEM/F12 medium from Corning cellgro™. In a 500ml bottle, 25ml of 5% horse serum
from Sigma® Life Science is added to the medium along with 100µl of 500µg/ml of
cholera toxin for a final concentration of 100ηg/ml. In addition, 1ml of 5mg/ml insulin
for a final concentration of 10µg/ml, 63µl of 4mg/ml of hydrocortisone for a final
concentration of 0.5µg/ml, and 50µl of 200µg/ml of EGF for a final concentration of
20ηg/ml are added. When detaching cells from cell culture plate, 0.25% of Tripsin
acquired from Sigma® Life Science.

2.2: Western Blot:
Protein extraction was achieved using Triton X. The protein concentration is then
quantified and normalized to insure equal loading into polyacrylamide gels. 8%
polyacrylamide gels were used to separate the proteins. Antibodies used were acquired
from Cell Signaling Technology®.

11

2.3: RNA Extraction:
MCF10A-Vec and MCF10A-HER2 cells were grown in 6cm cell culture plates to
90% confluency. TRIzol® was used to extract the RNA by adding 1mL per plate. The
cells were then scraped off using a scraper and put into a 1.5 ml centrifuge tubes. RNA
extraction from this point was done using TRIzol® protocol. RNA concentration was
measured using Epock plate reader (BioTek).

2.4: Poly-adenylation:
The RNA that was extracted was poly-adenylated using E.coli poly(A)
polymerase from New England Biolabs® inc. 2µg of total RNA was added with 1µl of
poly(A) polymerase. 1µl of 10mM adenosine-5’-triphosphate (ATP) from New England
Biolabs® inc. was also added. 1µl of recombinant ribonuclease inhibitor named
RNaseOut™ from Invitrogen was added to the mix. Then, 2µl 10X reaction buffer from
New England Biolabs® inc. was added. Finally, fill the reaction mix was filled to 20µl
with RNase-free water from Thermo Scientific. The samples were then incubated at 37°C
for 1 hour. After the poly-adenylation, 8µl of the poly-adenylated total RNA was mixed
with 6µl of RNase-free water. Added to the mix was 2µl of 10mM of dNTP from Bioline,
and 8 µl of 2.5µM of polyT adaptor primer to make a total volume of 24µl. The polyT
adaptor primer sequence is as follows:
GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN
Where N is any nucleotide and V is any nucleotide except thymine (T). The sample was
then incubated at 65°C for 5 minutes for the primer to anneal. The samples must then
immediately be chilled on ice.
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2.5: Quantitative reverse-transcription polymerase chain reaction:
For the reverse-transcription polymerase chain reaction (RT-PCR), the 24µl
product from the poly-adenylation step was used and 8µl of 5X first strand buffer from
Invitrogen was added to it. Additionally, 4µl of 0.1M DTT and 2µl of RNaseOut™ – both
from Invitrogen – was added to the mix for a total of 38µl. The mix was then brought up
to 37°C by incubating it for 2 minutes. 2µl of 1X M-MLV reverse transcriptase acquired
from Invitrogen brings the final volume of the reaction to 40µl. The reaction was then
incubated for 50 minutes at 37°C. The reaction was terminated by incubating the reaction
at 70°C for 15 minutes. Finally, the reaction was then diluted by bringing the total
volume to 400µl (Figure 2.1). For the quantitative polymerase chain reaction (QPCR),
10µl of RT² SYBR® Green ROX qPCR Mastermix from Qiagen was added. In addition,
2µl of cDNA from the previous RT-PCR was added along with 6µl of RNase-free water
and 1µl of a universal reverse primer with the following sequence:
GCGAGCACAGAATTAATACGAC
Finally, 1µl of a forward primer specific to the miRNA in question was added to
make a total reaction volume of 20µl. The reaction was run in an Applied Biosystem™
qPCR machine with the following parameters: Stage 1: 3 minutes hot start at 95°C. Stage
2: 15 seconds denaturing step at 95°C, followed by 30 seconds annealing step at 60°C,
and finally, the extension step was held for 35 seconds at 70°C. This stage was repeated
for 45 cycles.
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Figure 2.1: Polyadenylation and QRT-PCR assay:
Polyadenylation occurs after total RNA extraction. Poly A polymerase adds Adenosine to
the end of miRNAs. Annealing of the oligo-dT adaptor to make a cDNA with a universal
sequence to all miRNAs. Using miRNA specific forward primer is used on the cDNA to
amplify desired miRNAs.
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Chapter 3
Results

3.1: Many microRNAs are found to be regulated by overexpression of HER2:
For screening purposes, immortalized human breast cells called MCF10A-Vector
and its HER2 positive counterpart was used. To confirm whether the HER2 transformed
cells do produce the HER2 receptor, a western blot was performed for evidence (Figure
3.1). The MCF10A-HER2 indeed has a higher expression of the phosphorylated HER2
(p-HER2), which signifies the activation of the HER2 receptor in the cells. The activation
of HER2 triggers the activation of the downstream signaling pathway. This downstream
pathway activation is affirmed by the phosphorylation of Akt (p-Akt), a direct
downstream pathway of HER2, and the phosphorylation of Erk (p-ERK ½), which is
downstream of the MEK pathway. In addition, the p65 is a subunit of the NFκB and is
activated by phosphorylation when HER2 is overexpressed (p-p65). To further prove that
the downstream pathways are dependant on HER2, HER2 was knocked down using
siRNA. The result from the knock down shows a decrease in expression of HER2, p-Akt,
and p-ERK ½ but not p-p65. NFκB pathway can be regulated by many different pathways
other than HER2 which would explain why no change occurs in p-p65.
MCF10A-Vector and MCF10A-HER2 total RNA was used to screen for potential
miRNA that are differentially regulated by the overexpression of HER2. 303 miRNA
primers were created for 303 different miRNA.
15

With the cDNA created from the total RNA and the primers, the 303 miRNA
expression levels were measured between the MCF10A-Vector and MCF10A-HER2
using quantitative reverse-transcription polymerase chain reaction (QRT-PCR). The
results show how many folds the miRNAs have changed from MCF10A-Vector to
MCF10A-HER2 cells (Figure 3.2a). However, not all results from the QRT-PCR for the
miRNAs are accurate. Normally, the QRT-PCR product is run in an agarose gel to
determine if the product of each miRNA primer is correct based on size and number of
bands visible. The QRT-PCR product is between sixty five and seventy bases long
depending on the size of the mature miRNA being detected. Therefore, the correct size is
determined by observing if the product is the correct size, which should be between the
fifty base pair (bp) and the one hundred bp markers. The miRNAs in figure 3.2b show
sharp bands at the correct size with the exception of miR-22-3p. Therefore, miRNAs that
had the wrong size band – higher than roughly one hundred base pairs – or had multiple
bands were also eliminated. That is because multiple bands indicate a non-accurate
primer that has amplified a multitude of genes. For example, miR-214-3p (Figure 3.2c)
shows bands at the wrong size – higher than one hundred base pairs – indicating
inaccurate primer. Additionally, miRNAs that show no band, like miR-210-5p (Figure
3.2c), indicate low abundance of those particular miRNAs and are therefore, eliminated.
It is important to note that ideally we may be able to visualize a difference between the
band in the MCF10-Vector and MCF10-HER2 band like in miR-219-5p (Figure 3.2b).
However, the QPCR was run up to forty five cycles and possibly lead to saturation of the
amplified miRNAs.
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As a result, the miRNA screening has shrunk to 129 miRNAs that show a single
band in agarose gels at the correct size (Figure 3.3). Furthermore, expression of cDNA is
considered unreliable when the expression is detected passed thirty five cycles in QRTPCR. In addition, it is known that an up-regulation of only two fold change or higher and
a down-regulation of negative two fold change or lower are considered a significant
change in regulation. That is due to the general low abundance of each miRNA in a cell.
Therefore, miRNAs were eliminated that did not show significant up or down-regulation
and had detection at thirty five cycles or higher in both MCF10A-Vector and MCF10AHER2. Thus, out of these the remaining 129 miRNAs, fourteen miRNAs, were selected
which are considered the most reliable and strongest candidates (Figure 3.4).

3.2: microRNA in vitro regulation consistent with clinical data:
miRNA levels from 1,302 breast tumors were acquired from Dvinge’s group
where they collected the samples from European tumor banks (Dvinge et al 2013). The
data was sorted and selected for patients that have died of breast cancer regardless of
HER2 status. Compared with the data in Figure 3.4, only five miRNAs were found to
match the differential regulation in that the same miRNAs are either down or upregulated in both MCF10A-HER2 and HER2 positive tumor samples (Figure 3.5). miR181d and miR-195-5p show down-regulation in MCF10A-HER2 and in HER2 positive
tumor samples as compared with HER2 negative counterparts (Figure 3.5a, 3.5b, 3.5c). In
addition, miR-146a-5p shows instead an up-regulation in both the HER2-positive tumor
sample and MCF10A-HER2 (Figure 3.5a, 3.5d). Moreover, miR-34a and miR-452-5p
show up-regulation in MCF10A-HER2 and in HER2 positive tumor samples (Figure 3.5a,
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Figure 3.1: Western blot indicating HER2 overexpression in MCF10A-HER2
compared with MCF10A-Vector and its downstream pathways:
Western blot analysis indicating the HER2 overexpression in MCF10A-HER2 compared
to MCF10A-Vec. The overexpression causes the up-regulation of the downstream
pathways of HER2. MCF10A-HER2 siHER2 is knocked down for HER2 and the
downstream pathways are knocked down accordingly as compared to MCF10A-HER2
siCTRL.
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miRNA Screening
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Figure 3.2: Identification of differentially expressed miRNAs in HER2
overexpressing cells using QRT-PCR analysis:
MCF10A-Vector and HER2 were used to screen for differentially regulated miRNAs. a)
Screening of 303 miRNAs using qRT-PCR and measured according to fold change. b)
Agarose gel picture depicting the expression of a sample of qRT-PCR products from the
miRNA screening. c) A second agarose gel picture depicting the expression of a sample
of qRT-PCR products from the miRNA screening showing ideal size bands.
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Figure 3.3: Selected miRNAs based on qRT-PCR single correct product band size
and visibility:
From the 303 miRNA in the original screening, miRNAs that did not show a band, did
not have correct band size, and showed multiple bands were all eliminated. This leaves us
with 129 miRNAs that show a single band in the correct size.
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Fold Change
Figure 3.4: qRT-PCR of selected candidate miRNAs:
Differential expression of the selected candidate miRNA in MCF10A-HER2. The
miRNAs that have negative expression levels are considered down-regulated and have
lower levels in MCF10A-HER2 as compared with MCF10A-Vector. miRNAs that have
positive expression levels are considered up-regulated and have higher levels in
MCF10A-HER2 as compared with MCF10A-Vector.
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3.5e, 3.5f). Furthermore, the changes in the HER2-positive tumor samples are statistically
very significant for all five miRNAs as designated by their P-value.
After narrowing down the miRNAs in five candidates, these five miRNA
expression levels were stratified and sorted for each breast cancer subtype. In HER2
positive patients, miR-34a shows high levels of up-regulation, and, consistently, its
expression levels are highest in HER2 subtypes in comparison with the other breast
cancer subtypes (Figure 3.6a). The second up-regulated miRNA from the five candidates
is miR-146a-5p. It is observed that between the five different subtypes, miR-146a-5p
expression levels are highest in HER2, basal-like, and normal-like breast cancer subtypes
which could be possible due to their similar morphology (Figure 3.6b). The next miRNA
is miR-181d, and it is down-regulated in HER2 positive patients. In comparison with the
subtypes, miR-181d is down-regulated in HER2 subtypes compared to the luminal
subtypes. However, it shows no significant difference between the basal-like and normallike breast cancer subtypes (Figure 3.6c). The second down-regulated miRNA in HER2
positive patients is miR-195-5p. In comparison with the normal-like and luminal A breast
cancer subtypes, the expression level of miR-195-5p is down-regulated significantly
(Figure 3.6d). However, miR-195-5p expression levels show no difference between
HER2, luminal b, and basal-like subtypes. Finally, miR-452 is up-regulated in HER2
positive patients and is therefore also up-regulated in HER2 breast cancer subtype
compared to luminal A and B (Figure 3.6e).
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Figure 3.5: Relative expression levels of the five candidate miRNAs in HER2
positive and negative patient samples:
Expression levels in both MCF10A-HER2 and HER2 positive tumor tissue of five
candidate miRNAs. a) Shows the expression levels of these miRNAs in MCF10A-HER2
using QRT-PCR. b) Relative expression level of miR-181d between HER2 negative and
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Figure 3.6: Relative expression of selected candidate miRNAs in breast cancer
subtypes of tumor samples are differentially regulated in HER2 compared to
luminal subtypes:
Relative expression of miRNA distributed according to breast cancer subtype. Expression
levels of each miRNA in HER2 subtype is compared against each other subtypes. a) miR34a expression level. b) miR-146a-5p expression levels. c) miR-181d expression levels.
d) miR-195-5p expression levels. e) miR-452 expression levels.
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3.3: miR-34a and miR-452-5p have no correlation to HER2 positive patient survival:
Consistent with previous research regarding aggressiveness of HER2 positive
cancers, patients whose their tumor samples tested positive for HER2 have shown a
decrease in survival as compared with HER2 negative tumor samples (Figure 3.7). This
affirms the importance of understanding and treating HER2 positive cancers. On the
other hand, when it comes to the miRNAs that are affected by HER2 expression levels,
miR-34a and miR-452-5p do not show a significant effect on patient survival. In HER2
negative patients, higher levels of miR-34a increases patient survival percentage (Figure
3.8c). However, miR-34a does not seem to have any impact on overall patient survival
(HER2 positive and HER2 negative patients) or even HER2 positive patients. In other
words, there is no statistically significant percent survival difference between patients
with higher levels of miR-34a and patients with lower levels of miR-34a (Figure 3.8a,
3.8b). In addition, miR-452-5p seems to have no impact on breast cancer patient survival.
There is no significance of percent survival in general patients, HER2 positive patient
percent survival, or even HER2 negative patient percent survival depending on miR-4525p levels (Figure 3.9). However, this does not mean that these two miRNAs do not have a
significant role in HER2 overexpressing cancers. This just means that they do not have a
significant effect on patient survival.

3.4: Patient survival is significantly affected by three miRNAs:
Out of the five miRNAs that were differentially regulated in the same pattern in
both MCF10A-HER2 and HER2 positive tumor samples, only three showed a significant
impact on patient survivability. The first of these miRNAs is miR-181d. Although miR-
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Figure 3.7: Kaplan-Meier survival curve based on their HER2 status:
Blue survival curve shows 1129 patients with HER2 negative tumors. 173 Patients with
HER2 positive tumors are represented with the red survival curve. The curve is measured
in percent of patient survival versus the time in years. P-value < 0.0001 for the survival
plot.
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Figure 3.8: Kaplan-Meier survival curve according to miR-34a levels:
Blue survival curve shows patients with lower than average level of miR-34a. Red curve
shows patients survival with miR-34a levels that are higher than average. The curve is
measured in percent of patient survival versus the time in years. a) General patients’
percent survival based on the level of miR-34a (P-value = 0.0641). b) HER2 positive
patient’s percent survival dependent on miR-34a levels (P-value = 0.6573). c) Survival of
patients with HER2 negative tumors based on miR-34a levels (P-value = 0.0381).
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Figure 3.9: Kaplan-Meier survival curve based on miR-452-5p levels:
Impact of miR-452-5p levels on patient survival. Blue survival curve shows patients with
lower than average level of miR-452-5p. Red curve shows patients’ survival with miR34a levels that are higher than average. The curve is measured in percent of patient
survival versus the time in years. a) General patients’ percent survival dependent on miR452-5p levels (P-value = 0.7838). b) HER2 positive patients’ percent survival based on
miR-452-5p expression levels. c) HER2 negative patients’ percent survival based on
miR-452-5p levels.

28

181d shows no significant impact on HER2 positive patient survivability (Figure 3.10b),
it does show statistically significant impact on the survival of the general population of
patients and in HER2 negative patients’ survivability (Figure 3.10a, 3.10c). With miR181d, the higher its levels are, the higher the percentage of patient survival through time
for both HER2 negative patients and the general patient population. Therefore, this
indicates that miR-181d does have a significant role or target in the HER2 pathway that
affects patient survival positively. Therefore, when HER2 is overexpressed, it downregulates miR-181d causing it to be unable to function as efficiently. It is also important
to note that the number of patients that express higher than average miR-181d in HER2
positive patients (Figure 3.10b) is at a lower ratio than the number of patients expressing
higher than average miR-181d in the general patient population and in the HER2 negative
patients (Figure 3.10a, 3.10c). In the general patient population and in the HER2 negative
patient population, the number of patients in lower and higher than average expression of
miR-181d is nearly equivalent as opposed to the HER2 positive patients. This is due to
the fact that in HER2 positive patients, the overexpression of HER2 causes a significant
down-regulation of miR-181d to be below average levels where having a higher than
average expression level is an outlier.
The second miRNA that has a significant impact is miR-195-5p. miR-195-5p
shows no significant statistical impact on the percent survival of HER2 positive patients
(Figure 3.11b). However, the effect of miR-195-5p is visible when looking at the general
population of patients and HER2 negative patients (Figure 3.11a, 3.11c). As shown, miR195-5p expression levels are directly proportional to patient survivability in the general
patient population and in HER2 negative patients. Higher levels of miR-195-5p increases
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patient survival and lower levels of miR-195-5p decrease it. These results are similar to
that of miR-181d and would produce the same speculation that miR-195-5p targets an
oncogene. When HER2 is overexpressed, it down-regulates miR-195-5p, causing it to be
unable to efficiently inhibit the translation of the oncogene’s mRNA. Likewise, it is also
important to note the sample numbers for each population of patients. Unlike miR-181d,
miR-195-5p’s general patient population is not distributed in equal ratios between the
above and below average miR-195-5p expression (Figure 3.11a). The population of
HER2 negative patients is also not distributed evenly between miR-195-5p that is above
or below average expression levels (Figure 3.11c). However, when looking at the
population distribution in HER2 positive patients, we are able to notice that the number
of patients that are expressing lower than average miR-195-5p is more than the number of
patients expressing above average miR-195-5p (Figure 3.11b). This trend also follows
that of miR-181d in HER2 positive patients where the number of patients expressing
lower than average miR-181d is more than the patients expressing above average miR181d levels (Figure 3.10b). Like miR-181d, the reason for this distribution of patients in
HER2 positive patients is because HER2 overexpression causes a down-regulation of
miR-195-5p in most patients that an above average expression level is an outlier.
Finally, the third miRNA that is significantly impacting patient survivability is
miR-146a-5p. HER2 positive patients show no significant impact due to the levels of
miR-146a-5p (Figure 3.12b). However, as with the previous two miRNAs, the impact of
miR-146a-5p on survivability is most evident in the general patient population and HER2
negative patients (Figure 3.12a, 3.12c). For both the general patient population and HER2
negative patients, the higher the levels of miR-146a-5p, the lower the patients’ percent
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survival, making miR-146a-5p inversely proportional to patient survivability. Opposite
from what is observed in miR-181d and miR-195-5p, the number of patients expressing
above average miR-146a-5p is larger than the number of patients expressing lower than
average miR-146a-5p in HER2 positive patients (Figure 3.12b). That is due to the
overexpression of HER2 where it up-regulates miR-146a-5p in the majority of patients
and that patients that have lower than average miR-146a-5p expression are outliers.
However, the patient distribution between above and below average miR-146a-5p
expression in the general patient population shows a shift towards the lower than average
expression and HER2 negative population shows an even distribution.
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Figure 3.10: Kaplan-Meier survival curve based on miR-181d levels:
miR-181d’s levels’ effect on patient survival. Blue survival curve shows patients with
lower than average level of miR-181d. Red curve shows patients’ survival with miR-34a
levels that are higher than average. The curve is measured in percent of patient survival
versus the time in years. a) General patients’ percent survival based on the level of miR181d (P-value = 0.0034). b) Survival of patients with HER2 positive tumors based on
miR-181d levels (P-value = 0.2188). c) HER2 negative patient’s percent survival
dependent on miR-181d levels (P-value = 0.0371).
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Figure 3.11: Kaplan-Meier survival curve according to miR-195-5p levels:
miR-195-5p’s levels’ effect on patient survival. Blue survival curve shows patients with
lower than average level of miR-195-5p. Red curve shows patients’ survival with miR195-5p levels that are higher than average. The curve is measured in percent of patient
survival versus the time in years. a) General patients’ percent survival based on the level
of miR-195-5p (P-value < 0.0001). b) Survival of patients with HER2 positive tumors
based on miR-195-5p levels (P-value = 0.8362). c) HER2 negative patients’ percent
survival dependent on miR-195-5p levels (P-value = 0.0001).
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Figure 3.12: Kaplan-Meier survival curve according to miR-146a-5p levels:
miR-146a-5p’s levels’ effect on patient survival. Blue survival curve shows patients with
lower than average level of miR-146a-5p. Red curve shows patients’ survival with miR146a-5p levels that are higher than average. The curve is measured in percent of patient
survival versus the time in years. a) General patients’ percent survival based on the level
of miR-146a-5p (P-value = 0.0317). b) Survival of patients with HER2 positive tumors
based on miR-146a-5p levels (P-value = 0.3398). c) HER2 negative patients’ percent
survival dependent on miR-146a-5p levels (P-value = 0.0218).
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Chapter 4
Discussion

Since their discovery in 1993, miRNAs have been extensively studied for over
two decades with many exciting results (Lee et al 1993). However, there are over a
thousand human miRNAs that have so far been discovered and only a small portion has
been studied. Furthermore, within the small portion of miRNAs that have been studied,
there remains many areas of each single miRNA to be studied whether in regulation of
human physiology or the impact of these miRNAs on any type of cancer and its related
hallmarks. Typically, the most recently discovered miRNAs are the most extensively
studied due to their high abundance in cells. This high abundance is the reason for these
miRNAs’ early detection as compared to miRNAs that are detected much later in the
years. Moreover, miRNAs in HER2 positive breast cancers have not been intensively
studied leaving much information still unknown about HER2 positive breast cancer and
its interaction with miRNAs.
Starting off, it is important to note that our data shows the significance of how
overexpression of HER2 effects patient survival. In confirmation with many previous
research on HER2, it is shown in this population sample that overexpression of HER2
does indeed decrease patient survival with a very high statistical significance. MCF10A
cells are known as immortalized breast epithelial cells that can serve as non-cancerous
control cells. By overexpressing HER2 in MCF10A, the effect of overexpression can be
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studied as this overexpression is the only significant variable. As part of the screening,
many miRNAs are observed to be differentially regulated based on the HER2 expression
levels in MCF10A cells. However, not all miRNAs’ differential expression based on
HER2 translates into cancerous cells or tumor samples. Therefore, only a small number
of miRNA – specifically five – maintain their trend of expression. In other words,
miRNAs that are up-regulated in MCF10A-HER2, such as miR-146a-5p, miR-34a, and
miR-452-5p, are indeed up-regulated in HER2 positive tumor samples as compared with
HER2 negative tumor samples; and in addition, miRNAs that are down-regulated in
MCF10A-HER2 such as miR-181d and miR-195-5p, are in fact down-regulated in HER2
positive tumor samples as compared with HER2 negative tumor samples. Thereby, the
miRNAs from the original screening are narrowed down from around 303 miRNAs to
only five potential targets.
To further confirm the differential regulation of these miRNA based on HER2, we
can see in figure 3.4 that these miRNA are expressed in the same profile in HER2 breast
cancer subtype compared with luminal A and luminal B subtypes. It is worth noting that
miR-34a is the miRNA that shows the most significant difference in HER2 subtypes
compared to all other breast cancer subtypes. This indicates that miR-34a is possibly the
miRNA that is most affected by HER2 expression as the major regulator. Another
interesting miRNA when speaking about the breast cancer subtypes is miR-146a-5p. In
the HER2 subtypes, miR-146a-5p is significantly higher when compared with the luminal
subtypes as is expected. In addition, the luminal A and B subtypes show a surprisingly
very low expression level. This could be possibly due to the fact that the luminal subtypes
are ER positive. It has been shown that estrogen expression down-regulates the activation
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of NFκB by enhancing IκB levels (Xing et al 2012); and that with NFκB is positively
correlated with the expression of miR-146a-5p (Taganov et al 2006). However, the basallike breast cancer subtype shows an even higher expression level than that of the HER2
subtypes. This may be due to the fact that some basal-like tumors, though they are triplenegative, are HER2 enriched (Perou 2011). With this HER2 enrichment – coupled with
the absence of ER – miR-146a-5p expression is further amplified. The last three miRNAs
are miR-195-5p, 181d, and 452-5p, and they show their expected expression profile when
compared with the luminal subtypes. However, when compared with the basal-like and
normal-like subtypes, due to the fact that basal-like is enriched with HER2 and the
morphological resemblance and aggressiveness of normal-like, the HER2 subtype
miRNA expression levels show no difference. The major possibility is, due to the
similarity between these three subtypes, cross regulation from other pathways can affect
the expression of these three miRNA resulting in no significant difference.
However, these five miRNAs are nothing more than potential targets which need
further testing to validate as legitimate factors in patient survival. As such, when
searching through the data from the Dvinge group in regards to patient survivability, two
miRNAs begin to show their insignificance to patient survival between HER2 positive
and HER2 negative patients. The first of those miRNAs is miR-452-5p. Although miR452-5p shows up-regulation in MCF10A-HER2 and in HER2 positive tumor samples, its
effect on the patients from which the tumor samples were taken from is statistically
insignificant. This insignificance is evident in all of miR-452-5p on patient survival,
including general patient population survival based on miR-452-5p expression levels.
The second of those miRNAs is miR-34a. Even though miR-34a generally follows the
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same trend as miR-452-5p, it does have a statistically significant effect on HER2 negative
patient survival. However, miR-34a does not show any significant effect on patient
survival in both the general patient population and on HER2 positive patient survival.
This does not mean that its effect on the HER2 negative patient survival can be ignored;
it can simply be that it is not the major player of patient survival but a co-contributor.
Finally, while these two miRNAs do not have a major effect on patient survival, they can
have other effects, such as tumor initiation or tumor progression.
The next three miRNAs from the original five are observed to have a very
statistically significant impact on patient survival. The first of these three miRNAs is
miR-146a-5p. The fact that there have been many reports of miR-146a-5p being upregulated in many cancers, including breast cancer, helps support the fact that miR-146a5p can have a significant impact on patient survival in HER2 positive breast cancer
patients (Labbaye & Testa 2012). In this study, miR-146a-5p is indeed up-regulated in
HER2 positive breast cancer patients and in MCF10A-HER2. This indicates that miR146a-5p is up-regulated directly or indirectly by HER2 overexpression.
Furthermore, it is observed that the up-regulation of miR-146a-5p decreases
patient survival in both HER2 negative patients and in the general patient population.
This means that miR-146a-5p is an oncomir should target a tumor suppressor gene that
would control the tumor aggressiveness, for example. However, miR-146a-5p does not
cause a significant change in HER2 positive patients. The reason for this is because in
HER2 positive patients generally observe above average miR-146a-5p levels due to the
overexpression of HER2. Therefore, any increase in up-regulation is not going to have a
higher decrease in patient survival because miR-146a-5p is already above the threshold.
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The second miRNA that has considerable impact on patient survival is miR-1955p. Like miR-146a-5p, miR-195-5p has been extensively studied, especially in breast
cancer, as it was found to be down-regulated (Ouyang et al 2014). It has also been
suggested as a possible diagnostic target for breast cancer (Luo et al 2014). Thus, miR195-5p is solidified as an important target in breast cancer and supports the data in this
study. In accordance with previous research, miR-195-5p is down-regulated in MCF10AHER2 and also in HER2 positive. These results thus supports the idea that miR-195-5p is
regulated by the level of HER2 expression. However, it is unknown how this regulation
occurs whether it is direct or indirect.
Moreover, miR-195-5p is shown to be directly proportional to the percent survival
of the general patient population and the HER2 negative patients – the same two samples
as miR-146a-5p. This means that the lower the levels of miR-195-5p, the lower the
chance for patient survival. This further means that miR-195-5p is a tumor suppressor
miRNA that targets an oncogene that would normally have an adverse effect on the
patient. Like miR-146a-5p, miR-195-5p shows no significant effect on patient percent
survival in HER2 positive patients. The reason is also similar to miR-146a-5p in that
miR-195-5p is down-regulated below the threshold with the overexpression of HER2 in
HER2 positive patients; and that when the levels are already below the threshold, any
change in the levels would not have any more impact than what has already been
observed.
The final and third miRNA that has a significant effect on patient survivability is
miR-181d. Unlike the previous two miRNAs, miR-181d has not been extensively studied.
The amount of information and connection between miR-181d and cancer is scarce, and
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it is even more so in HER2 positive breast cancers. However, it has been observed that
the miR-181 family (miR-181a, miR-181b, miR-181c, and miR-181d), more precisely
miR-181c, is activated by HER2 expression (Lowery et al 2009). Even though miR-181c
is possibly co-expressed or repressed with miR-181d, there has not been much research
done regarding this co-expression or repression. Therefore, it is plausible that miR-181d
is down-regulated with the overexpression of HER2 in both MCF10A-HER2 and HER2
positive patients.
Like miR-195-5p, miR-181d is shown to be directly proportional to patient
survival in both HER2 negative patients and the general patient population. These two
populations are again the same two populations affected by the two miRNAs that have
been previously discussed. Along the same previous lines, the higher levels of miR-181d
the higher the chances for patient survivability. Therefore, miR-181d can be classified as
a tumor suppressor miRNA targeting an oncogene. Similar to the two previously
discussed miRNA, miR-181d shows no significant effect on patient survival in HER2
positive patients. The explanation for this phenomenon is the same with miR-195-5p in
that miR-181d is down-regulated below the threshold with the overexpression of HER2
in HER2 positive patients; and that when the levels are already below the threshold, any
change in the levels would not have any more impact than what has already been
observed.
Finally it is important to understand how all these miRNA tie in together in the
HER2 pathway and how they affect the behavior of HER2 positive breast cancer. From
previous research, HER2 has been discovered to directly activate the NF-κB independent
of PI3K/Akt protein by activating IκB kinase α (IKKα). Activation of IKKα causes the

40

phosphorylation of IκB, which stops its inhibitory activity on NF-κB. Interestingly,
induction of miR-146a-5p is positively dependent on the activation of NF-κB (Taganov et
al 2006). Furthermore, ERBB receptor feedback inhibitor 1 (ERRFI1) which can target
and inhibit HER2 (Segatto et al 2011), is suggested to be a potential target of miR-146a5p (Garcia et al 2011). Although this potential target needs experimental confirmation, if
it is true, then this interaction can explain why HER2 positive cells can keep
overexpressing HER2 without hindrance; and that would be due to miR-146a-5p
inhibiting ERRFI1. However, the complex pathway does involve at least one more
component and that is miR-195-5p. Research has shown that miR-195-5p down-regulates
the NF-κB pathway by targeting and thereby inhibiting IKKα (Ding et al 2013).
Therefore, it would down-regulate the expression of miR-146a-5p. Unfortunately, miR195-5p is down-regulated and has no effect on the expression of miR-146a-5p in HER2
overexpressing tumors. However, there are two unknown factors in this pathway we
propose (Figure 4.1). These two factors are how both miR-195-5p and miR-181d are
regulated by HER2, whether it is directly or indirectly by HER2’s many down-stream
proteins.
In conclusion, with better understanding of the HER2 pathway, we are better able
to treat HER2 positive tumors. With the understanding that miR-146a-5p, miR-181d, and
miR-195-5p are differentially regulated by HER2, it is possible to use these miRNAs as
potential targets for drugs designed to inhibit miR-146a-5p for example. It is also
possible to hinder tumor progression by inducing the production of miR-195-5p or miR181d. Finally it is possible to use any of these miRNA as possible biological markers for
tumors that can be detected early.
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Figure 4.1: Proposed regulation model of HER2 pathway by the selected miRNAs:
HER2 pathway involving miR-195-5p, miR-146a-5p, and miR-181d. Inhibition of miR195-5p by HER2 directly or indirectly is unknown. Inhibition of miR-181d directly or
indirectly is unknown. miR-195-5p targets IKKα which eventually effects miR-146a-5p.
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